Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 16, 2020 16:30 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Announces Closing of Public Offering of Common Stock

NEW YORK, March 16, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
March 06, 2020 08:01 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Receives Notice of Allowance for Composition of Matter Patent for SLS-007

NEW YORK, March 06, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
February 19, 2020 08:02 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics to Participate in Two Upcoming Investor Conferences in March

Cowen 40th Annual Health Care Conference on March 2nd-4th in Boston, MARoth Capital 32nd Annual Conference on March 16th-17th in Laguna Niguel, CA NEW YORK, Feb. 19, 2020 (GLOBE NEWSWIRE) --...
February 13, 2020 16:30 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Announces Closing of Public Offering of Common Stock

NEW YORK, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
February 10, 2020 20:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Announces Pricing of $5 Million Public Offering of Common Stock

NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
January 28, 2020 08:02 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Announces Update to Parkinson’s Disease Program SLS-007

Delivery of SLS-007 to Utilize an Adeno-Associated Virus (AAV) VectorSLS-007 to Become Seelos’ Second Gene Therapy Program Focused on Parkinson’s NEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Seelos...
November 01, 2019 10:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics to Participate in Upcoming Investor Conferences in December

NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Evercore ISI 2nd...
October 18, 2019 09:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics to Participate in Upcoming Investor Conference in November

NEW YORK, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Jefferies 2019...
October 15, 2019 09:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Announces the Addition of Scott Applebaum as Lead Strategic Regulatory Consultant

NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today announced the addition of Scott Applebaum to its team as lead...
August 23, 2019 09:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Announces Pricing of $6.7 Million Registered Direct Offering

NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it has entered into a securities purchase...